Cefixime trihydrate  (Synonyms: FR-17027 trihydrate; FK-027 trihydrate; CL-284635 trihydrate)

Cefixime trihydrate (FR-17027 trihydrate) is an antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections^[1][2].

Cefixime trihydrate shows great antibacterial activity against clinical isolates of Salmonella typhi, with a MIC90 value of 0.25 μg/mL, and is also active against β-lactamase producing Amoxicillin (HY-B0467A)-resistant strains^[3].
Cefixime trihydrate is also active against Enterobacteriaceae, such as Haemophilus influenzae, and Neisseria gonorrhoeae^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cefixime (0.75-60 mg/kg, oral gavage) trihydrate reduces the bacterial burden in mice challenged with FA1090 (ESC-susceptible strain)^[4].
Cefixime (50 or 150 mg/kg, oral gavage) trihydrate changes the structure and abundance of the gut microbiota of C57BL/6J mice, specifically, a reduction in the diversities of the microbial community and decreasing to one preponderant Firmicutes phylum^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

507.50

C₁₆H₂₁N₅O₁₀S₂

125110-14-7

Solid

White to off-white

O=C(C(N12)=C(C=C)CS[C@@H]2[C@H](NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)C1=O)O.[H]O[H].[H]O[H].[H]O[H]

Room temperature in continental US; may vary elsewhere.

• [1]. Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):958-62.  [Content Brief]

  [2]. Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80.  [Content Brief]

  [3]. Matsumoto Y, et al. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J Infect Chemother. 1999 Sep;5(3):176-179.  [Content Brief]

  [4]. Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01644-18.  [Content Brief]

  [5]. Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model. Microbiol Res. 2017 Jul;200:14-24.  [Content Brief]

  [6]. Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221-8.  [Content Brief]